Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Broken String Biosciences ("Broken String"), a leader in advancing gene editing safety, today opened its Catalyst Early ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

International collaborations, refined gene-editing protocols, and targeted immunologic maneuvers keep the cancer gene therapy ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

Exagamglogene autotemcel (exa-cel) gene therapy offers a potential cure for severe sickle cell disease, now available on NHS.

The National Institute for Health and Care Excellence (NICE) has approved a one-off gene editing therapy to treat severe sickle cell disease (SCD) in people 12 years and over. In final draft guidance1 ...